HC Wainwright Reiterates Buy Rating on GOSS
HC Wainwright maintains its buy rating for GOSS with a $2 price target, a 1083.43% upside from the current price.
Key Points
- On June 25, 2026, HC Wainwright reiterated its buy rating on GOSS, setting a price target of $2.
- HC Wainwright's $2 price target implies 1083.43% upside from Gossamer Bio, Inc.'s ($GOSS) current $0.17 share price.
- Shares of GOSS traded near $0.17 on Thursday, reflecting the company's current market conditions.
- Several insiders, including Daniel Thomas and Quisel John, each acquired 115,000 shares on June 4, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating on GOSS, setting a price target of $2. The analyst, Patrick R. Trucchio, confirmed this stance on June 25, 2026. The stock traded near $0.17 on Thursday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in GOSS
BlackRock, Inc. reduced its holdings in GOSS by 230,183 shares, leaving it with 16,826,695 shares valued at about $5.53 million, a 1.3% decrease. Kalehua Capital Management LLC opened a new position with 10,236,293 shares worth approximately $3.36 million. AQR Capital Management LLC significantly increased its stake by 9,007,657 shares, resulting in a total of 10,126,897 shares valued at $3.33 million, marking an 804.8% increase. Vanguard Capital Management LLC also initiated a new position, acquiring 9,394,593 shares worth about $3.09 million. Meanwhile, Octagon Capital Advisors LP cut its holdings by 6,165,371 shares, ending with 7,750,000 shares valued at $2.55 million, a 44.3% decrease.
Insider Buying and Selling at Gossamer Bio, Inc.
On June 4, 2026, several insiders at GOSS, including Daniel Thomas, John Quisel, Steven Nathan, Russell Cox, Skye Drynan, and Sandra Milligan, each purchased 115,000 shares. These transactions were not part of a pre-planned trading scheme.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. maintained its buy rating on GOSS with a $2 price target. Previously, on May 19, 2026, Barclays maintained a sell rating with a $0.28 target. Earlier this year, on March 6, 2026, HC Wainwright & Co. had also maintained a buy rating with a higher target of $5.
Bottom Line
HC Wainwright's reiterated buy rating and $2 target suggest confidence in GOSS's prospects. Institutional investors and insiders have shown varied interest, with some increasing positions while others reduced or initiated new stakes. As always, these ratings and transactions reflect past decisions and may not indicate future performance.
Get Gossamer Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GOSS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.